Skip subpage navigation
In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs. The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.
| Meeting Date |
Review Type |
Drug Classes/New Drugs Under Review/Information for Manufacturers |
Meeting Window for Manufacturers to give Clinical/Cost Presentations |
|
February 2014
|
Class Review |
Pulmonary-1 Agents |
January 2014 |
| Class Review |
PEC Class: Gastrointestinal-1 Agents |
| Class Review |
PEC Class: Pancreatic Enzyme Agents |
| Designated Newly Approved Drugs |
Mirabregon, Forfivo XL, Brintellix, Fetzima, Khedezla |
|
May 2014
|
Class Review |
Osteoporosis Agents |
March/April 2014 |
| Class Review |
Nasal Allergy Agents |
| Class Review |
Pulmonary-1 Agents |
| Desingated Newly Approved Drugs |
Arcapta, Myrbetriq, Farxiga, Solvaldi, Uceris, Eliquis, Zorvolex, Quillivant XR |
|
August 2014
|
Class Review |
Multiple Sclerosis Agents |
Solicitation Cancelled |
| Class Review |
Targeted Immunomodulary Biologics |
June 2014 |
| Designated Newly Approved Drugs |
Quillivant XR, Tanzeum |
June 2014 |
|
November 2014
|
Class Revew |
Pulmonary Arterial Hypertension Agents |
Solicitation Cancelled |
| Class Review |
Multiple Sclerosis Agents |
September 2014 |
| Class Review |
Self Monitoring Blood Glucose Strips |
Send new or update information
|
| Designated Newly Approved Drugs |
Anoro Ellipa, Prolensa, Simbrinza, V-Go |
September 2014 |
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: April 25, 2024